These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 7511017

  • 21. Engraftment with peripheral blood stem cells using noncontrolled-rate cryopreservation: comparison with autologous bone marrow transplantation.
    Rosenfeld CS, Gremba C, Shadduck RK, Zeigler ZR, Nemunaitis J.
    Exp Hematol; 1994 Mar; 22(3):290-4. PubMed ID: 7509292
    [Abstract] [Full Text] [Related]

  • 22. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
    Engelhardt M, Winkler J, Waller C, Lange W, Mertelsmann R, Henschler R.
    Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
    [Abstract] [Full Text] [Related]

  • 23. Peripheral blood stem cell (PBSC) mobilization with chemotherapy followed by sequential IL-3 and G-CSF administration in extensively pretreated patients.
    Kolbe K, Peschel C, Rupilius B, Després D, Burger K, Sklenar I, Färber L, Huber C, Derigs HG.
    Bone Marrow Transplant; 1997 Dec; 20(12):1027-32. PubMed ID: 9466274
    [Abstract] [Full Text] [Related]

  • 24. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH, Fay JP, Christiansen NP, Pinero L, Shah D, Stephan M, Herzig GP.
    Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
    [Abstract] [Full Text] [Related]

  • 25. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
    Weaver CH, Schwartzberg L, Li W, Hazelton B, West W.
    Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
    [Abstract] [Full Text] [Related]

  • 26. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
    Moskowitz CH, Glassman JR, Wuest D, Maslak P, Reich L, Gucciardo A, Coady-Lyons N, Zelenetz AD, Nimer SD.
    Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
    [Abstract] [Full Text] [Related]

  • 27. Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation.
    Kiss JE, Rybka WB, Winkelstein A, deMagalhaes-Silverman M, Lister J, D'Andrea P, Ball ED.
    Bone Marrow Transplant; 1997 Feb; 19(4):303-10. PubMed ID: 9051238
    [Abstract] [Full Text] [Related]

  • 28. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.
    Tarella C, Di Nicola M, Caracciolo D, Zallio F, Cuttica A, Omedè P, Bondesan P, Magni M, Matteucci P, Gallamini A, Pileri A, Gianni AM.
    Bone Marrow Transplant; 2002 Dec; 30(11):725-32. PubMed ID: 12439694
    [Abstract] [Full Text] [Related]

  • 29. Harvesting, characterization, and culture of CD34+ cells from human bone marrow, peripheral blood, and cord blood.
    Van Epps DE, Bender J, Lee W, Schilling M, Smith A, Smith S, Unverzagt K, Law P, Burgess J.
    Blood Cells; 1994 Dec; 20(2-3):411-23. PubMed ID: 7538347
    [Abstract] [Full Text] [Related]

  • 30. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
    Buckstein R, Imrie K, Spaner D, Potichnyj A, Robinson JB, Nanji S, Pennel N, Reis M, Pinkerton P, Dubé I, Hewitt K, Berinstein NL.
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
    [Abstract] [Full Text] [Related]

  • 31. Factors affecting the mobilization of primitive and committed hematopoietic progenitors into the peripheral blood of cancer patients.
    Schneider JG, Crown JP, Wasserheit C, Kritz A, Wong G, Reich L, Norton L, Moore MA.
    Bone Marrow Transplant; 1994 Dec; 14(6):877-84. PubMed ID: 7536069
    [Abstract] [Full Text] [Related]

  • 32. Primitive hematopoietic progenitor cells are present in peripheral blood autografts.
    Tong J, Gianni AM, Siena S, Srour EF, Bregni M, Hoffman R.
    Blood Cells; 1994 Dec; 20(2-3):351-62; discussion 362-3. PubMed ID: 7538339
    [Abstract] [Full Text] [Related]

  • 33. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM, Visani G, Leopardi G, Motta MR, Rizzi S, Testoni N, Curti A, Tura S.
    Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
    [Abstract] [Full Text] [Related]

  • 34. Treatment of poor marrow graft function with allogeneic CD34+ cells immunoselected from G-CSF-mobilized peripheral blood progenitor cells of the marrow donor.
    Arseniev L, Tischler HJ, Battmer K, Südmeier I, Casper J, Link H.
    Bone Marrow Transplant; 1994 Nov; 14(5):791-7. PubMed ID: 7534162
    [Abstract] [Full Text] [Related]

  • 35. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy.
    Sosman JA, Stiff PJ, Bayer RA, Peliska J, Peace DJ, Loutfi S, Stock W, Oldenburg D, Unverzagt K, Bender J.
    Bone Marrow Transplant; 1995 Nov; 16(5):655-61. PubMed ID: 8547862
    [Abstract] [Full Text] [Related]

  • 36. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
    Crump M, Couture F, Kovacs M, Saragosa R, McCrae J, Brandwein J, Huebsch L, Beauregard-Zollinger L, Keating A.
    Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
    [Abstract] [Full Text] [Related]

  • 37. Filgrastim post-chemotherapy mobilizes more CD34+ cells with a different antigenic profile compared with use during steady-state hematopoiesis.
    Möhle R, Pförsich M, Fruehauf S, Witt B, Krämer A, Haas R.
    Bone Marrow Transplant; 1994 Nov; 14(5):827-32. PubMed ID: 7534163
    [Abstract] [Full Text] [Related]

  • 38. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation.
    Zumberg MS, Leather HL, Nejame C, Meyer C, Wingard JR.
    Cytotherapy; 2002 Nov; 4(6):531-8. PubMed ID: 12568989
    [Abstract] [Full Text] [Related]

  • 39. The use of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignancies.
    Vose JM, Bierman PJ, Kessinger A, Coccia PF, Anderson J, Oldham FB, Epstein C, Armitage JO.
    Bone Marrow Transplant; 1991 Feb; 7(2):139-43. PubMed ID: 1675592
    [Abstract] [Full Text] [Related]

  • 40. Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant.
    Bolwell BJ, Goormastic M, Yanssens T, Dannley R, Baucco P, Fishleder A.
    Bone Marrow Transplant; 1994 Dec; 14(6):913-8. PubMed ID: 7536072
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.